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Abstract
Weight gain is a well-established side effect of both conventional and newer anti-psychotic drugs, but the 
cause is not well understood. Recent studies correlate obesity with the presence or absence of particular 
genetic sequences in the gut microbiota. We identified strong associations between protein targets of 
antipsychotics and microbiota sequences directly related to weight regulation in human body, leading to a 
potential metagenomic mechanism of action. Further experimental study is recommended.
Introduction
First generation antipsychotic drugs (FGAs – butyrophenones, phenothiazenes such as chlorpromazine, 
and thioxanthenes) are associated with a variety of side effects including weight gain1-3 and related 
conditions such as non–insulin-dependent diabetes mellitus4.  Hypotheses on the role of antipsychotics in 
regulating weight of patients is widely documented5,6. A study in 1988  of over 200 patients7 showed a 
fourfold increase in weight-gain as a side effect of receiving antipsychotics at least four times that in the 
general population. Second generation antipsychotics (SGAs) also show equal or higher weight gain than 
FGAs, with Clozapine and Olzapine the most highly implicated8-10 including in children and adolescents11.
Amongst other SGAs, risperidone and quetiapine appear to have intermediate effects where as 
aripiprozole and ziprasidone are associated with little or no significant weight gain. Studies on the risks 
and the nature of side-effects of both FGAs and SGAs have shown substantial link with obesity, but the 
mechanisms responsible are still unidentified12. 
It is known that presence or absence of certain gut microbial communities regulate total body fat 
of the host, as they affect the amount of energy extracted from the diet13-18. Studies on lean and obese mice
and humans suggest that the gut microbiota influences the efficiency of calorie harvest from diet and 
further the energy usage and storage. The studies have linked obesity with two dominant bacterial 
divisions in gut micro-biota: bacteroidetes and firmicutess. A study was carried out on 154 individuals to 
study the fecal microbial communities of adult female monozygotic and dizygotic twin pairs concordant 
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for leanness or obesity, and their mothers. The study identified a set of obesity related protein sequences 
(differential genes) in human gut microbe, which participate in mechanisms related to the development of 
fat, insulin resistance and low-grade inflammation that characterize obesity. V2 and V6 16S rRNA gene 
sequencing datasets and 21 obesity-associated protein sequences from E.rectale, E.eligens, B.theta3731, 
B.theta7330, and B.WH2 were released (dataset from this study)19. Gut microbes can cause variation in 
the toxicity and efficacy of drugs in individuals and affect absorption and bioavailability of drugs in the 
host, and thus metagenomic considerations are likely to be important in developing more effective drugs 
and in future personalized health-care paradigms. Over the last two decades the dietary–microbe–host 
interactions and role of gut microbes affecting physiological processes regulating body weight, have 
received intense investigation 23-25. Further, novel methods to manipulate commensal microbial 
composition through combinations of antibiotics, probiotics and prebiotics are being tested for therapeutic
approach26-27. 
Materials and Methods
In this work we sought to examine whether weight regulation,  as a side effect could be explained by 
potential drug action on microbial genes, which are known to be differentially associated with obesity19. 
Since there is very little published data on the action of drugs on microbial genes, our approach involved 
identifying human genes with high sequence similarity to these differential genes, and examining the 
bioactivity profiles of drugs against these human genes (with the assumption that drugs with known 
bioactivity against the highly similar human genes have a high chance of activity against the microbial 
counterparts). Sequence data on 3,19,812 proteins from 89 frequent microbial genomes was extracted 
from the KEGG database28-30, as a reference set and was added to sequence data for the 21 differential 
obesity genes identified in the obesity study19. We carried out a sequence similarity search on this 
combined set using BLASTP31 against sequences for enzyme and drug targets in humans from 
DrugBank32 with criteria33 for a match being significance  E-value <10e-2 and percent identity > 47. 741 
matching human genes were found, 40 matching differential microbial genes and 701 matching the 
reference set genes. We used approved drugs dataset from DrugBank database to extract the drugs known 
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to bind to these genes 34-35. We identified 145 and 611 FDA approved drugs targeting our set of the 
differential and non-differential matching genes respectively. Finally, we profiled side-effects of these 
selected  drugs using the SIDER database36. 
Results and Discussion
The identified drugs were categorized based on DrugBank annotations and the frequency of (occurrence) 
drug categories related to differential and non-differential gut microbial gene list were shortlisted. Out of 
9 drugs with weight gain as a side effect, 7 were of the antipsychotic class. The antispychotics with 
weight gain side effects showed a significant (p<0.001) association with the differential genes when 
compared with other drugs (mean 6.625 associations versus 1.229), with the one antispsychotic without a 
registered weight gain side effect (fencamfamine) having just 3 differential gene associations. 
Interestingly, the antispychotics also show a significantly lower (p<0.001) association with 
non-differential genes than the other drugs (mean 5.75 associations versus 16.772). Table 1 shows a list of
the antipsychotic drugs with associated differential human genes (i.e. those with high sequence similarity 
to the bacterial genes with weight-gain associations), organized by bacterium of the bacterial genes. All of
the associated genes are from Bacteriodes thetaiotaomicron and Eubacterium rectale. Both of these have 
an important influence on host energy balance and there are indications of a direct link with body weight 
regulation, although the pathways involved are still under investigation37-40. The gene functions cover 
metabolite biosynthesis, transport, catabolism, metabolism and cellular metabolism. 
Conclusion
We thus propose a plausible metagenomic mechanism of action for the weight regulation side 
effects of antipsychotics through their potential interruption of pathways in the gut Bacteriodes 
thetaiotaomicron and Eubacterium rectale bacteria. We believe further investigation is warranted, 
including direct testing of the effects of the drugs on these bacteria, examination of weight regulation 
side-effects of these drugs on subpopulations of patients who have different gut states41 or ethnic 
populations with gut bacterial diversity, and on the association of these bacteria with weight regulation in 
the body. Depending on the outcome of these studies, probiotic supplement of these bacteria in patients 
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taking antipsychotics may be evaluated. The application of this methodology to other outcomes, including
cancers, is also being evaluated. 
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Table 
Zipradisone Bacteriodes thetaiotaomicron {CYP1A2, CYP2R1, CYP17A1, PGD};
Chlorpromazine Bacteriodes thetaiotaomicron {Steryl-sulfatase, SLC35D1, cyaC, 
CYP17A1, CYP17A2, CYP2R1, pph}; Eubacterium rectale {pph, fixL, 
phoQ, envZ, TM_1359, fixL}
Palonosetron Bacteriodes thetaiotaomicron {SLC35D1, cyaC, CYP2R1, PRODH}; 
Eubacterium rectale {pph, fixL, cheA, cyaC, ABCA1, CYP2E1}
Clozapine Bacteriodes thetaiotaomicron {CYP17A1, PGD, phoQ}
Promazine Bacteriodes thetaiotaomicron {cyaC, CYP2R1, PRODH, CYP17A1}
Thioridazine Bacteriodes thetaiotaomicron {SLC35D1, cyaC, CYP2R1, CYP17A1, 
PGD, CYP1A2}; Eubacterium rectale {CYP2E1, envZ, TM_1359}
Olanzapine Bacteriodes thetaiotaomicron {SLC35D1, cyaC, PRODH, CYP17A1, 
PGD, pph, CYP1A2}
Table 1. Antipsychotic drugs with human genes which (i) are binding targets for the drugs and (ii) have 
high sequence similarity to gut bacteria genes differentially associated with weight gain. Genes are 
organized by the parent bacterium of the bacterial genes. 
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